Chugai Pharmaceutical : Voting Results (Extraordinary Report) of the 112th Annual General Meeting of Shareholders

Extraordinary Report

March 31, 2023

(TRANSLATION)

Note for readers of this English translation

On March 31, 2023, Chugai Pharmaceutical Co., Ltd. filed its Japanese-language Extraordinary Report (Rinji Houkokusho) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 112th Annual General Meeting of Shareholders held on March 30, 2023 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 112th Annual General Meeting of Shareholders (the "Meeting") held on March 30, 2023, Chugai Pharmaceutical Co., Ltd. (the "Company") submits this Extraordinary Report under the provisions of Article 24-5 ， Paragraph 4，of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc. (the "Report").

2. Contents of the Report

• (1) Date when the Meeting was held:March 30, 2023

• (2) Matters for resolution

  • First Proposal: Appropriation of Surplus

    Year-end dividend

    JPY 40 per share of common stock of the Company

  • Second Proposal: Election of Four (5) Directors

    Elect Fumio Tateishi, Hideo Teramoto, Christoph Franz, James H. Sabry, and Teresa A. Graham as Directors of the Company.

  • Third Proposal: Election of Two (2) Audit & Supervisory Board Members

Elect Shigehiro Yamada and Yumiko Waseda as Audit & Supervisory Board

Members of the Company.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals: Results of the resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	14,922,146	3,489	0	99.98%	Approved
Second Proposal Fumio Tateishi Hideo Teramoto Christoph Franz James H. Sabry Teresa A. Graham	14,529,273 14,533,885 14,395,571 14,134,720 14,149,380	396,358 391,746 498,089 758,929 744,269	0 0 31,970 31,970 31,970	97.34% 97.37% 96.45% 94.70% 94.80%	Approved Approved Approved Approved Approved
Third Proposal Shigehiro Yamada Yumiko Waseda	14,832,412 14,922,105	93,212 3,523	0 0	99.37% 99.98%	Approved Approved

Notes: Requirements for the approval of each proposal are as follows:

• 1) The resolution for the First Proposal must be adopted by the majority of the votes of the shareholders present who are entitled to exercise their voting rights.

• 2) The resolution for the Second and Third Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.

(4) Reason why a portion of the voting rights held by the shareholders present at the

Meeting held on March 30, 2023 was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 30, 2023, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 30, 2023; and the voting rights of the shareholders present at the Meeting held on March 30, 2023, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.